Hyo-Jin Jeong1, Robert J Vandenberg, Christopher W Vaughan. 1. Pain Management Research Institute, Kolling Institute of Medical Research, Northern Clinical School, University of Sydney at Royal North Shore Hospital, NSW, Australia. jeong@med.usyd.edu.au
Abstract
BACKGROUND AND PURPOSE: The arachidonyl-amino acid N-arachidonyl-glycine (NAGly) is an endogenous lipid, generated within the spinal cord and producing spinally mediated analgesia via non-cannabinoid mechanisms. In this study we examined the actions of NAGly on neurons within the superficial dorsal horn, a key site for the actions of many analgesic agents. EXPERIMENTAL APPROACH: Whole cell patch clamp recordings were made from lamina II neurons in rat spinal cord slices to examine the effect of NAGly on glycinergic and NMDA-mediated synaptic transmission. KEY RESULTS: N-arachidonyl-glycine prolonged the decay of glycine, but not β-alanine induced inward currents and decreased the amplitude of currents induced by both glycine and β-alanine. NAGly and ALX-1393 (inhibitor of the glycine transporter, GLYT2), but not the GLYT1 inhibitor, ALX-5407, produced a strychnine-sensitive inward current. ALX-5407 and ALX-1393, but not NAGly prolonged the decay phase of glycine receptor-mediated miniature inhibitory postsynaptic currents (IPSCs). NAGly prolonged the decay phase of evoked IPSCs, although to a lesser extent than ALX-5407 and ALX-1393. In the presence of ALX-1393, NAGly shortened the decay phase of evoked IPSCs. ALX-5407 increased and NAGly decreased the amplitude of evoked NMDA-mediated excitatory postsynaptic currents. CONCLUSIONS AND IMPLICATIONS: Our results suggest that NAGly enhanced inhibitory glycinergic synaptic transmission within the superficial dorsal horn by blocking glycine uptake via GLYT2. In addition, NAGly decreased excitatory NMDA-mediated synaptic transmission. Together, these findings provide a cellular explanation for the spinal analgesic actions of NAGly.
BACKGROUND AND PURPOSE: The arachidonyl-amino acid N-arachidonyl-glycine (NAGly) is an endogenous lipid, generated within the spinal cord and producing spinally mediated analgesia via non-cannabinoid mechanisms. In this study we examined the actions of NAGly on neurons within the superficial dorsal horn, a key site for the actions of many analgesic agents. EXPERIMENTAL APPROACH: Whole cell patch clamp recordings were made from lamina II neurons in rat spinal cord slices to examine the effect of NAGly on glycinergic and NMDA-mediated synaptic transmission. KEY RESULTS:N-arachidonyl-glycine prolonged the decay of glycine, but not β-alanine induced inward currents and decreased the amplitude of currents induced by both glycine and β-alanine. NAGly and ALX-1393 (inhibitor of the glycine transporter, GLYT2), but not the GLYT1 inhibitor, ALX-5407, produced a strychnine-sensitive inward current. ALX-5407 and ALX-1393, but not NAGly prolonged the decay phase of glycine receptor-mediated miniature inhibitory postsynaptic currents (IPSCs). NAGly prolonged the decay phase of evoked IPSCs, although to a lesser extent than ALX-5407 and ALX-1393. In the presence of ALX-1393, NAGly shortened the decay phase of evoked IPSCs. ALX-5407 increased and NAGly decreased the amplitude of evoked NMDA-mediated excitatory postsynaptic currents. CONCLUSIONS AND IMPLICATIONS: Our results suggest that NAGly enhanced inhibitory glycinergic synaptic transmission within the superficial dorsal horn by blocking glycine uptake via GLYT2. In addition, NAGly decreased excitatory NMDA-mediated synaptic transmission. Together, these findings provide a cellular explanation for the spinal analgesic actions of NAGly.
Authors: Hong Yin; Alan Chu; Wei Li; Bin Wang; Fabiola Shelton; Francella Otero; Deborah G Nguyen; Jeremy S Caldwell; Yu Alice Chen Journal: J Biol Chem Date: 2009-03-13 Impact factor: 5.157
Authors: Jesica R Williams; Anna L Khandoga; Pankaj Goyal; James I Fells; Donna H Perygin; Wolfgang Siess; Abby L Parrill; Gabor Tigyi; Yuko Fujiwara Journal: J Biol Chem Date: 2009-04-14 Impact factor: 5.157
Authors: Zhe Yang; Karin R Aubrey; Iris Alroy; Robert J Harvey; Robert J Vandenberg; Joseph W Lynch Journal: Biochem Pharmacol Date: 2008-08-07 Impact factor: 5.858
Authors: Heather B Bradshaw; Neta Rimmerman; Sherry Shu-Jung Hu; Valery M Benton; Jordyn M Stuart; Kim Masuda; Benjamin F Cravatt; David K O'Dell; J Michael Walker Journal: BMC Biochem Date: 2009-05-21 Impact factor: 4.059
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739